• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Iconovo

1.15 SEK

-0.43 %

Less than 1K followers

ICO

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.43 %
+1.77 %
+0.44 %
+0.88 %
0.00 %
-42.50 %
-95.72 %
-98.43 %
-96.47 %

Iconovo operates in the medical technology sector. The company develops inhalers for medical use. The company's products are used in the treatment of asthma and coal, where the inhalers consist of powder-based medicine. The products are licensed and sold under various brands. In addition to product development, there is expertise in pharmaceutical formulation. The company was founded in 2013 and has its headquarters in Lund.

Read more
Market cap
110.6M SEK
Turnover
139.68K SEK
Revenue
1.11M
EBIT %
-3,883.78 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
20.8
2026

Interim report Q2'26

23.10
2026

Interim report Q3'26

26.2
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release23 hours ago

Iconovo and Lonza sign Strategic Collaboration Agreement

Iconovo
Press release4/24/2026, 3:52 PM

DNB Carnegie Access: Iconovo: Limited progress – Q1 review

Iconovo
Regulatory press release4/24/2026, 6:30 AM

QUARTERLY REPORT Q1 2026

Iconovo

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release4/14/2026, 1:40 PM

Anders Månsson is appointed CEO

Iconovo
Regulatory press release3/17/2026, 3:05 PM

Iconovo publishes outcome of exercise of warrants series TO 1

Iconovo
Regulatory press release3/10/2026, 7:05 AM

Iconovo’s rights issue is registered – conversion of BTA into shares

Iconovo
Regulatory press release3/2/2026, 3:20 PM

Iconovo announces final outcome in the rights issue

Iconovo
Regulatory press release2/27/2026, 5:20 PM

Iconovo publishes preliminary outcome of rights issue and announces recalculation of warrants series TO 1

Iconovo
Press release2/24/2026, 7:50 PM

Iconovo and Lonza signs LOI regarding strategic collaboration

Iconovo
Press release2/16/2026, 6:01 PM

DNB Carnegie Access: Iconovo: Still needs proof – Q4 review

Iconovo
Press release2/13/2026, 1:45 PM

DNB Carnegie Access: Iconovo - Q4 2025 - Intervju

Iconovo
Regulatory press release2/13/2026, 7:30 AM

The subscription period in Iconovo's rights issue begins today

Iconovo
Regulatory press release2/12/2026, 1:30 PM

Iconovo publishes information document regarding rights issue of shares

Iconovo
Regulatory press release2/12/2026, 7:30 AM

Year-end report 1 January - 31 December 2025

Iconovo
Press release1/15/2026, 9:15 AM

Iconovo has initiated a new feasibility study for ICOone® Nasal in collaboration with multinational company

Iconovo
Press release1/13/2026, 12:40 PM

EPO declares intention to approve ICOpre® patent application

Iconovo
Regulatory press release12/22/2025, 9:00 AM

Nomination Committee appointed at Iconovo AB

Iconovo
Regulatory press release12/16/2025, 11:45 AM

Iconovo announces that the terms and conditions for allotment of shares in directed issue are met

Iconovo
Press release11/26/2025, 11:47 AM

DNB Carnegie Access: Iconovo: Raises capital

Iconovo
Regulatory press release11/25/2025, 8:05 PM

Iconovo carries out a directed issue of shares of approx. SEK 25 million and a rights issue of shares of approx. SEK 24.6 million, which is covered to 100% by subscription undertakings and guarantee commitments

Iconovo